ERBB2 and neoplasm: The most common tumor receptor subtype was HR positive and ERBB2 negative (64.8%), followed by HR positive and ERBB2 positive (6.2%), HR negative and ERBB2 negative (4.9%), and HR negative and ERBB2 positive (1.9%).